Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.

EF 2022-23

Résumé
Supervisor: Christel Renoux, McGill University Colorectal (CRC) and pancreatic (PC) cancers are both deadly cancers, ranking in the top three of the leading causes of cancer death in Canada, with significant healthcare costs. Smoking, alcohol abuse, and inappropriate dietary habits are common risk factors, but the contribution of medications such as anticoagulants in the occurence of both cancers has been poorly explored. Direct oral anticoagulants (DOACs) are a specific type of anticoagulants, recently introduced in the prevention of thrombosis in non-valvular atrial fibrillation patients. These drugs present a reasonable drug-drug interaction profile, don't require regular monitoring, and are orally administered, all of which make them more attractive and widely used compared to conventional anticoagulants such as vitamin K antagonists (VKAs). However, few animal studies have signaled an increased risk of colorectal and pancreatic cancers with these drugs. These results have prompted several studies in humans which have resulted in mixed findings, some studies have found a greater risk of both cancers while others have not. Further, these studies had notable problems including residual bias, confounding by indication, and insufficient power. The primary objective of my study is to separately assess the risk of CRC and PC among DOACs users vs non-users. Secondarily, I will assess the risk of CRC and PC associated with DOACs vs VKAs, as well as the risk of CRC and PC associated with concurrent use of proton pump inhibitors and DOACs compared vs DOACs alone. To conduct this study, I will use the Clinical Practice Research Datalink (CPRD), a primary care database that contains anonymized medical records of over 60 million patients over around 2500 general practices in the United Kingdom (UK). I will be performing a scientific literature review, protocol development, data analysis, writing a thesis, and presenting articles at national and international conferences.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
474475
Name
Damba Joseph Junior
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Anticoagulants; Cohort Study; Colorectal Cancer; Direct Oral Anticoagulants; Pancreatic Cancer; Population-Based; Vitamins K Antagonists
Abstract
Supervisor: Christel Renoux, McGill University Colorectal (CRC) and pancreatic (PC) cancers are both deadly cancers, ranking in the top three of the leading causes of cancer death in Canada, with significant healthcare costs. Smoking, alcohol abuse, and inappropriate dietary habits are common risk factors, but the contribution of medications such as anticoagulants in the occurence of both cancers has been poorly explored. Direct oral anticoagulants (DOACs) are a specific type of anticoagulants, recently introduced in the prevention of thrombosis in non-valvular atrial fibrillation patients. These drugs present a reasonable drug-drug interaction profile, don't require regular monitoring, and are orally administered, all of which make them more attractive and widely used compared to conventional anticoagulants such as vitamin K antagonists (VKAs). However, few animal studies have signaled an increased risk of colorectal and pancreatic cancers with these drugs. These results have prompted several studies in humans which have resulted in mixed findings, some studies have found a greater risk of both cancers while others have not. Further, these studies had notable problems including residual bias, confounding by indication, and insufficient power. The primary objective of my study is to separately assess the risk of CRC and PC among DOACs users vs non-users. Secondarily, I will assess the risk of CRC and PC associated with DOACs vs VKAs, as well as the risk of CRC and PC associated with concurrent use of proton pump inhibitors and DOACs compared vs DOACs alone. To conduct this study, I will use the Clinical Practice Research Datalink (CPRD), a primary care database that contains anonymized medical records of over 60 million patients over around 2500 general practices in the United Kingdom (UK). I will be performing a scientific literature review, protocol development, data analysis, writing a thesis, and presenting articles at national and international conferences.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Damba, Joseph Junior
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~